Precise tumor targeting and labeling with a flourescent mucin 4 antibody for imaging patient-derived pancreatic cancer in a mouse model

Michael A. Turner; Hiroto Nishino; Siamak Amirfakhri; Sukhwinder Kaur; Kavita Mallya; Robert M. Hoffman; Surinder Batra; Michael Bouvet

doi:10.1117/12.2610524

4 March 2022 Precise tumor targeting and labeling with a flourescent mucin 4 antibody for imaging patient-derived pancreatic cancer in a mouse model

Michael A. Turner, Hiroto Nishino, Siamak Amirfakhri, Sukhwinder Kaur, Kavita Mallya, Robert M. Hoffman, Surinder Batra, Michael Bouvet

Author Affiliations +

Proceedings Volume 11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII; 1194305 (2022) https://doi.org/10.1117/12.2610524
Event: SPIE BiOS, 2022, San Francisco, California, United States

Abstract

Introduction The 5 year survival rate of pancreatic cancer is <10%. Most patients have metastatic disease at time of diagnosis, often to the liver. Innovative imaging modalities, i.e. fluorescence guided surgery (FGS), may better appreciate metastatic disease and guide treatment. Mucin 4 (MUC4), a glycoprotein, is found in 89% of pancreatic cancers and absent in normal pancreatic tissue making it a candidate for tumor targeting in FGS. In the present study, a fluorescently-labeled MUC4 antibody preferentially targets patient pancreatic cancer in a mouse model. Methods and Materials A MUC4 antibody was conjugated to the infrared dye IRDye800CW (LICOR, Lincoln, NE) to synthesize MUC4-IR800. A high MUC4 expressing patient-derived hepatic metastatic pancreatic tumor (Panc Met) was divided into 1mm3 tumor fragments and implanted under the skin of the nude mouse. After the tumors grew ~5mm3, two mice received 50 μg and two mice received 75 μg of MUC4-IR800 via tail vein injection. Daily in-vivo imaging was performed with the Pearl Trilogy Imager (LICOR, Lincoln, NE) for 3 days. Tumor to background ratios (TBR) were calculated using skin as background. Results MUC4-IR800 selectively imaged the Panc Met tumors (see figure below). TBRs for all time points and doses were <2. The 75 μg arm had higher TBRs at 24 and 72 hours. At 48 hours, the TBRs were the same. Conclusion This present study demonstrated the successful targeting of a patient hepatic metastatic pancreatic cancer mouse model with MUC4-IR800. This has potential to improve metastatic pancreatic cancer detection. Future studies will be conducted with orthotopic models.

Conference Presentation

Citation Download Citation

Michael A. Turner, Hiroto Nishino, Siamak Amirfakhri, Sukhwinder Kaur, Kavita Mallya, Robert M. Hoffman, Surinder Batra, and Michael Bouvet "Precise tumor targeting and labeling with a flourescent mucin 4 antibody for imaging patient-derived pancreatic cancer in a mouse model", Proc. SPIE 11943, Molecular-Guided Surgery: Molecules, Devices, and Applications VIII, 1194305 (4 March 2022); https://doi.org/10.1117/12.2610524

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available